asthma
Teva team up with IBM to tackle two challenges facing the pharma industry
October 27, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cloud Computing, Teva Pharmaceutical, asthma, ibm
Teva Pharmaceuticals and IBM have announced a partnership that will use IBM Watson Health Cloud with the aim of finding …
AstraZeneca forced to abandon Phase II trial
October 12, 2016Research and Development AstraZeneca, Synairgen, asthma, cold, common cold
Synairgen, a respiratory drug discovery and development company, has developed a drug, AZD9412, alongside AstraZeneca to treat and prevent severe …
AZ’s first respiratory biologic meets primary endpoints in Phase III trials
September 5, 2016Research and Development, Sales and Marketing AstraZeneca, asthma, benralizumab, biologic, respiratory, severe asthma
AstraZeneca has presented Phase III data at the European Respiratory Society (ERS) international congress which shows that trial biologic benralizumab …
UK asthma spending tops £1.1 billion
August 30, 2016Research and Development asthma, university of edinburgh
The University of Edinburgh has released a report that claims UK health service spending on asthma has reached £1.1 billion …
Vectura asthma treatment fails at Phase III
August 30, 2016Manufacturing and Production, Research and Development asthma, inhaler, phase III, phase III failure, vectura
Respiratory drug specialist Vectura’s asthma treatment Flutiform was unsuccessful in meeting the primary endpoint in its Phase III trial conducted …
EU grants marketing authorisation for Teva’s asthma drug Cinqaero
August 19, 2016Medical Communications, Sales and Marketing EU, Teva, approval, asthma, cinqaero, eosinophilic
The European Commission has granted marketing authorisation for Teva’s Cinqaero (reslizumab), as an odd-on therapy in adult patients with severe …
‘Game changer’ asthma pill sees significant reduction in severe symptoms
August 8, 2016Research and Development, Sales and Marketing Fevipiprant, Novartis, asthma, university of Leicester
A study at the University of Leicester has found that Fevipiprant (QAW039), the first new asthma pill for nearly 20 …
GSK says asthma drug Breo shows superior results over standard care in major study
May 24, 2016Research and Development, Sales and Marketing COPD, GSK, asthma, breo, drug trial
UK drugmaker GlaxoSmithKline (LSE: GSK) on Tuesday said inhaled medicine Breo proved significantly better than standard care in a major …
Teva announces FDA approval for asthma injection, Cinqair
March 24, 2016Research and Development, Sales and Marketing FDA, Teva, approval, asthma, cinqair
The US Food and Drug Administration has approved Cinqair (reslizumab), an injection for patients with severe asthma developed by Teva …
AstraZeneca buys rights to Orexo respiratory programme
March 21, 2016Sales and Marketing AstraZeneca, COPD, asthma, orexo
AstraZeneca has bought the rights to a respiratory programme from Sweden’s Orexo for $5 million. The deal centres on the …
GSK’s asthma drug meets primary goal in safety study for children
March 17, 2016Research and Development Advair Diskus, GSK, asthma, drug trial
GlaxoSmithKline (LSE: GSK) said on Thursday its asthma drug met the primary end point in a second study for children. …
GSK says long-term study for Nucala backs safety profile
March 8, 2016Manufacturing and Production, Research and Development GSK, GlaxoSmithKline, Nucala, asthma
UK pharma major GlaxoSmithKline (LSE: GSK) said its asthma drug, Nucala (mepolizumab) showed a similar safety profile in a long-term …
Researchers question price of GSK’s Nucala
December 23, 2015Research and Development GSK, HEOR, ICER, Nucala, asthma, cost-effective, health economics, health economics outcomes research
GSK is charging up to four times more for its recently approved asthma drug Nucala than is justified by cost-effectiveness …
GSK collaborates on ‘smart inhaler’ technology for respiratory trials
December 3, 2015Research and Development COPD, GSK, Propeller, Propeller Health, asthma, clinical trials, ellipta, inhalers, smart drugs, smart inhalers
GSK has entered the ‘smart drug’ industry by partnering with a health technology company to develop a sensor for use …
GSK gets European approval for asthma treatment Nucala
December 3, 2015Research and Development GSK, Nucala, asthma
GlaxoSmithKline has received marketing authorisation from the European Commission for Nucala as an add-on treatment for severe refractory eosinophilic asthma …
Latest content
EnteroBiotix appoints former GSK Chief Medical Officer to board
AI: an early warning system for patient safety
Highlighting the value of lab research for healthcare innovation
